Pfizer Pipeline – Our Medicines in Development

Our pipeline of new medicines in development is one of the largest in the pharmaceutical industry, focusing on a broad range of unmet medical needs. Pfizer historically has invested more than $7 billion annually in the research and development of new products across more therapeutic areas than any other company in our industry. Relying on the strength of our pipeline and scientific talent, Pfizer has generated a steady stream of breakthroughs over the years. And now, with our recent acquisition of Wyeth Pharmaceuticals, we have broadened our pipeline to include more promising treatment opportunities in areas such as small molecules, vaccines, and biopharmaceuticals. Our researchers continue to work around the clock and around the globe to ensure the best medicines for our patients in the years to come.

Pfizer Pipeline as of March 31, 2009

Read press release issued April 2, 2009

Download a PDF of the product candidates in Wyeth's human prescription medicine pipeline as of May 6, 2009. Content includes:

• New chemical entities in the Wyeth portfolio from initial discovery (Phase 0) through to first major approval in the United States or Europe.
• Chemical entities and medicines that have been removed from active status since the last pipeline report.

Wyeth Pipeline as of May 6, 2009